X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Catiolanze® is a preservative-free latanoprost 50μg/mL eye drop cationic emulsion. The active substance latanoprost, a prostaglandin F2α analogue, is a selective proteinoid FP receptor agonist which reduces the IOP by increasing the outflow of aqueous humor.
Lead Product(s): Latanoprost
Therapeutic Area: Ophthalmology Product Name: Catiolanze
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 17, 2023
Details:
Through acquisition, Harrow expands its ophthalmic portfolio by gaining certain U.S. and Canadian commercial rights for Flarex (fluorometholone acetate), Natacyn (natamycin), Tobradex ST (tobramycin and dexamethasone), Verkazia (cyclosporine) and Cationorm PLUS.
Lead Product(s): Fluorometholone Acetate
Therapeutic Area: Ophthalmology Product Name: Flarex
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Harrow
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition October 24, 2023
Details:
Under the agreement, Visiox gain rights to product manufacturing, commercialization, and sales of Omlonti (omidenepag isopropyl), an eye drop for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.
Lead Product(s): Omidenepag Isopropyl
Therapeutic Area: Ophthalmology Product Name: Omlonti
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Visiox Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 18, 2023
Details:
Through acquisition, Harrow expands its ophthalmic portfolio by gaining certain U.S. and Canadian commercial rights for Flarex (fluorometholone acetate), Natacyn (natamycin), Tobradex ST (tobramycin and dexamethasone), Verkazia (cyclosporine) and Cationorm PLUS.
Lead Product(s): Fluorometholone Acetate
Therapeutic Area: Ophthalmology Product Name: Flarex
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Harrow
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition July 17, 2023
Details:
STN1011101, a preservative-free combination eye drop of tafluprost 0.0015% and timolol 0.5%. It is being developed for lowering intraocular pressure of patients with open-angle glaucoma or ocular hypertension.
Lead Product(s): Tafluprost,Timolol Maleate
Therapeutic Area: Ophthalmology Product Name: STN1011101
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 08, 2023
Details:
Cationorm® Plus (glycerol) is a sterile, preservative-free, artificial tear containing the novel Novasorb® technology. As the only artificial tear that uses positive cationic emulsion to hold hydration in place, it protects, hydrates and lubricates the eye.
Lead Product(s): Glycerine,Tyloxapol API,Detalan
Therapeutic Area: Ophthalmology Product Name: Cationorm Plus
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2022
Details:
OMLONTI® (omidenepag isopropyl ophthalmic solution) 0.002%, is a relatively selective prostaglandin E2 (EP2) receptor agonist, indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Lead Product(s): Omidenepag Isopropyl
Therapeutic Area: Ophthalmology Product Name: Omlonti
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: UBE Corporation
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 26, 2022
Details:
Verkazia (cyclosporine) is a prescription-only, uniquely formulated cationic nanoemulsion that provides improved ocular bioavailability of cyclosporine, which has been shown to be effective in the management of VKC.
Lead Product(s): Cyclosporine
Therapeutic Area: Ophthalmology Product Name: Verkazia
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 02, 2022
Details:
Santen will be responsible for all development and commercialization costs and activities related to the products in the territories covered by the agreement with the exception of a post-marketing clinical study to be conducted by Aerie in Europe for Rhopressa and Rocklatan.
Lead Product(s): Netarsudil
Therapeutic Area: Ophthalmology Product Name: Rhopressa
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Alcon Inc
Deal Size: $168.0 million Upfront Cash: $88.0 million
Deal Type: Expanded Collaboration December 07, 2021
Details:
The agreement aims for SYD-101, Sydnexis’ investigational proprietary low dose atropine sulfate formulation, for Europe, Middle East and Africa (EMEA), is currently undergoing a phase III clinical trial, the STAAR study, in Europe and the US to help control myopia progression.
Lead Product(s): Atropine Sulfate
Therapeutic Area: Ophthalmology Product Name: SYD-101
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Sydnexis
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 10, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
